The dilated cardiomyopathy therapeutics market is anticipated to grow with a CAGR of nearly 3.6% during the forecast period. the main factors attributing to the expansion of the dilated cardiomyopathy therapeutics market are increasing anticipation and increasing prevalence of heart problems. Furthermore, the increasing number of individuals affected by heart muscle infections, along side the drug or alcoholic abuse also are the main factors that help in driving the expansion of the market. As the incidence of cardiovascular diseases is increasing which is directly proportional to the market growth. Whereas the side effects of dilated cardiomyopathy therapeutics that cause serious discomfort to the patients are restraining the market.

Top Driver: Growing demand for ready to eat food will drive the market growth

Rising incidences of congestive coronary failure across the world may be a prominent growth driver for dilated cardiomyopathy therapeutics market as DCM is one among the leading causes of coronary failure . Globally, dilated cardiomyopathy accounts for about 30% to 40% of the entire congestive coronary failure cases annually . due to the alarming rise in incidences of congestive coronary failure , several companies have initiated clinical test studies to develop therapeutics specifically for dilated cardiomyopathy. as an example , Array BioPharma in 2015 is conducting a phase II clinical trial study for its drug candidate ARRY-371797 for DCM treatment. Additionally, Celladon Corporation in 2014 completed its phase II clinical trial study of MYDICAR for dilated cardiomyopathy treatment. Success of those clinical studies will boost the expansion and demand for dilated cardiomyopathy therapeutics market in forthcoming years. However, promising gene therapy and availability of implantable devices (implantable cardioverter defibrillators (ICDs), heart pumps and pacemakers) are major restraints to the DCM therapeutics market

Angiotensin II receptor blockers is predicted to Dominate the expansion of the Market

Angiotensin II receptor blockers acquire the most important market share followed by beta-blockers. this is often attributed to the high demand for blockbuster drugs in dilated cardiomyopathy treatment, especially in developed regions. Aldosterone antagonists recorded a high rate of growth thanks to the identified positive impact of aldosterone antagonists when utilized in combination with either ARBs or ACE inhibitors in reducing the progression of Duchenne dystrophy (DMD). Approval for this indication would further accelerate the general sales of aldosterone antagonists, which successively would positively impact market growth. The other driving factors of the segment also are associated with the increasing prevalence of heart diseases. Therefore because the prevalence of heart diseases increases the expansion of the market increases too.

  North America Dominates the Market and Expected to grow in the Forecast Period

North America is predicted to dominate the general dilated cardiomyopathy therapeutics market, throughout the forecast period. the expansion is thanks to the rising incidence of cardiovascular diseases, well-established insurance policies and therefore the availability of advanced healthcare infrastructure are the main factors.

In the North America region, the us holds the most important market share thanks to factors like an increasing number of geriatric populations, along side a growing number of heart diseases within the country, which is anticipated to stimulate the demand during this region. Therefore because the number of cardiovascular diseases increases the marketplace for dilated cardiomyopathy also increases.

Players to Focus on Dilated Cardiomyopathy Therapeutics Market

Key players within the global DCM market include

• Array BioPharma, Inc.,
• AstraZeneca plc,
• Celladon Corporation,
• GlaxoSmithKline plc,
• Janssen Pharmaceuticals, Inc.,
• Merck & Co., Inc.,
• Novartis International AG,
• Pfizer, Inc.,
• Sanofi S.A.,
• Teva Pharmaceutical Industries Ltd.
• Vericel Corporation

Scope of the Report

By Drug

• Aldosterone antagonists
• Angiotensin-converting enzyme (ACE) inhibitors
• Angiotensin II receptor blockers (ARBs)
• Beta-blockers
  

By Pipeline

• ARRY-797
• ixCELL-DCM
• MYDICAR

By Region

• North America
• Europe
• Asia Pacific
• SAMEA

Key Reasons to Purchase this Report 

1. It provides a technological development map over time to understand the growth rate of the industry.

2. The report offers a dynamic method to various factors that drive or restrain the growth of the market.

3. It renders definite analysis for changing competitive dynamics.

4. It builds a seven-year estimate based on how the market is predicted to grow.